Trial Profile

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 20 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trametinib (Primary) ; Doxorubicin liposomal; Letrozole; Paclitaxel; Tamoxifen; Topotecan
Indications Carcinoma; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms LOGS

Most Recent Events

13 Nov 2025 Status changed from active, no longer recruiting to completed.
03 Dec 2024 Planned End Date changed from 11 Oct 2024 to 11 Oct 2025.
12 Oct 2023 Planned End Date changed from 11 Oct 2023 to 11 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com